HTLV, a multi organ oncovirus.


Journal

Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 20 08 2021
revised: 03 06 2022
accepted: 06 06 2022
pubmed: 11 6 2022
medline: 10 8 2022
entrez: 10 6 2022
Statut: ppublish

Résumé

Human T lymphotropic virus (HTLV-I) is a retrovirus that has been recognized as a causative agent of two crucidal diseases, HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T cell Leukemia-Lymphoma (ATLL). The virus not only induces those diseases in a small proportion of HTLV-I carriers (3-5%) but also it is associated with other diseases such as HTLV-I-Associated Arthropathy (HAAP), Cutaneous T Cell Lymphoma (CTCL), Graves' disease, uveitis, polymyositis, chronic respiratory diseases, lymphadenitis and dermatitis. Furthermore, HTLV related and accelerated disorders were more investigated, and the factors that might implicate in the development or progression of diseases have been discussed. We founded 13 categories of non-associated disease in studies such as Reproductive Disorders, Coronary Artery Disease (CAD), non -ATLL lymphoma, Co-infection, non-HAM/TSP neurological associated disease, non ATLL cutaneous associated disease, Autoimmune-Inflammatory related disease, Kidney disease, Liver disease, Respiratory disease, TB disease and Thyroid disease. With regard to the reviewed studies suggested HTLV-I disorders can divide into three manifests; related, accelerated and associated disease. However, interaction between HTLV-I infection and host immune response was complicated and vague. Some infectious patients indicated the involvement of inflammatory response of immune system, but in other individuals function of anti-inflammatory elements was observed. For a better understanding of this classification, more systematic studies should be designed and need to provide a global network to control and prevent HTLV affiliated diseases.

Identifiants

pubmed: 35688412
pii: S0882-4010(22)00235-2
doi: 10.1016/j.micpath.2022.105622
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105622

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Samaneh Ramezani (S)

Inflammation and Inflammatory Diseases Research Center, Mashhad University of Medical Sciences, Iran.

Seyed Abdolrahim Rezaee (SA)

Inflammation and Inflammatory Diseases Research Center, Mashhad University of Medical Sciences, Iran.

Zahra Farjami (Z)

Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical, Mashhad, Iran.

Neshat Ebrahimi (N)

Laboratory of Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Hasaneen Kudhair Abdullabass (HK)

Department of Pharmacology, Alkut University College, Iraq.

Mohammad Ismael Ibrahim Jebur (MI)

Republic of Iraq Ministry of Health, Directorate Wasit of Health, Iraq.

Houshang Rafatpanah (H)

Inflammation and Inflammatory Diseases Research Center, Mashhad University of Medical Sciences, Iran.

Mohammad Mehdi Akbarin (MM)

Inflammation and Inflammatory Diseases Research Center, Mashhad University of Medical Sciences, Iran. Electronic address: akbarinmm961@mums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH